MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance

CONCLUSION: - MG53 may be a novel biomarker of glucose dysregulation associated with β-cell dysfunction, likely improving our ability to identify, among high-risk subjects, those more likely to develop T2DM.PMID:34678488 | DOI:10.1016/j.diabet.2021.101292

Source: Diabetes and Metabolism - October 22, 2021 Category: Endocrinology Authors: Cristina Bianchi Francesco Raggi Chiara Rossi Simona Frontoni Riccardo C Bonadonna Stefano Del Prato Anna Solini Source Type: research